Expert Insights On CGT Formulation

  1. Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors 3/5/2026

    Intratumoral injection bypasses the tumor’s physical defenses entirely, killing cancer cells and creating a personalized immune response that destroys solid tumors.

  2. A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026? 1/30/2026

    In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.

  3. The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs 1/15/2026

    The cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).

  4. In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors 12/23/2025

    By injecting lipid-based nanoparticles encapsulating mRNA and encoding the CAR directly into the bloodstream, developers can effectively reprogram the patient's own immune cells in situ.

  5. Powering Cell Therapies With RNA: A New Code For Engineered Immunity 12/19/2025

    RNA is redefining cell therapy engineering—enabling transient, programmable control of immune and stem cells while simplifying manufacturing, improving safety, and accelerating scalable, virus-free workflows.

  6. Strained Manufacturing, Complexity Stymie In Vivo Progress 12/4/2025

     Explicitly mapping delivery challenges to the associated GMP process steps converts biological risk into operational risk.

  7. To Fight Cancer, Gene Editing Needs To Solve Its Delivery Problem 12/4/2025

    The choice of delivery dictates the complexity of manufacturing, which in turn determines the eventual cost and accessibility of the therapy.

  8. Formulation And Delivery Considerations For Cell And Gene Therapies 11/25/2025

    How can we ensure cell and gene therapies are truly transformative for patients? Success depends on the right combination of formulation, preparation, and delivery.

  9. Rethinking The "3:1 Rule" In LNP Production 11/21/2025

    A new two-step, ideal-mixing strategy from MIT researchers shows how operating briefly in unstable regions of LNP assembly can unlock precise control of particle size and shape—advancing next-gen RNA manufacturing.

  10. Emerging RNA Delivery Strategies For Solid Tumor Oncology 11/20/2025

    RNA shows promise in solid tumors, but delivery remains the core challenge. New targeting and delivery strategies aim to overcome tumor barriers and unlock RNA’s full therapeutic potential.